Top

Published in:

01-09-2012 | Original Article

Increased expression and function of P-glycoprotein in peripheral blood CD56+ cells is associated with the chemoresistance of non-small-cell lung cancer

Authors: Li Han, Ya Feng Wang, Yan Zhang, Ning Wang, Xiao Juan Guo, Jing Ke Yang, Kui Peng Wang, Su Na Liu, Qing Xia Fan, Ke Li, Jin Hua Jiang, Qing Duan Wang

Published in: Cancer Chemotherapy and Pharmacology | Issue 3/2012

Abstract

Purpose

Chemoresistance is common among non-small-cell lung cancer (NSCLC), P-glycoprotein (P-gp), encoded by the human multi-drug-resistant MDR1 gene, and multidrug-resistance protein 1 (MRP1) might be major contributors. The aim of the present study was to develop an effective method to investigate the expression and function of P-gp in the peripheral CD56+ cells in order to clarify their correlation with the chemoresistance in NSCLC.

Methods

Using microbead technology and a RT-qPCR methodology, we evaluated the expression levels of P-gp and MRP1 in the purified CD56+ cells in the chemoresistance and chemo-naive NSCLC patients compared with that in the healthy volunteers. Flow cytometric analysis was used to investigate the changes of P-gp function in the CD56+ cells between the three cohorts.

Results

The MDR1 gene expression was elevated markedly (twofold–tenfold), and P-gp function was increased in the chemoresistance cohort compared with the chemo-naive and the healthy cohorts; whereas there was only about two times averagely elevated for the MRP1 gene expression. No statistical significance (p > 0.05) was seen with respect to the expression of MDR1 and MRP1, the function of P-gp between the chemo-naive and the healthy cohorts.

Conclusions

P-gp in peripheral CD56+ cells demonstrated possible clinical relevance as predictive biomarkers for the identification of chemoresistance in NSCLC, while MRP1 may not play a significant role in the drug resistance in NSCLC. The potential applications for this finding are provided evidence to screen the potential P-gp reversors and to diagnose and manage the chemoresistance in NSCLC patients.

Jemal A, Bray F, Center MM et al (2011) Global cancer statistics. CA Cancer J Clin 61(2):69–90PubMedCrossRef

Molina JR, Yang P, Cassivi SD et al (2008) Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc 83(5):584–594PubMed

Roy S, Kenny E, Kennedy S et al (2007) MDR1/P-glycoprotein and MRP-1 mRNA and protein expression in non-small cell lung cancer. Anticancer Res 27(3A):1325–1330PubMed

Berger W, Setinek U, Hollaus P et al (2005) Multidrug resistance markers P-glycoprotein, multidrug resistance protein 1, and lung resistance protein in non-small cell lung cancer: prognostic implications. J Cancer Res Clin Oncol 131(6):355–363PubMedCrossRef

Scheper RJ, Broxterman HJ, Scheffer GL et al (1993) Overexpression of a M(r) 110,000 vesicular protein in non-P-glycoprotein-mediated multidrug resistance. Cancer Res 53(7):1475–1479PubMed

Merk J, Rolff J, Dorn C et al (2011) Chemoresistance in non-small-cell lung cancer: can multidrug resistance markerspredict the response of xenograft lung cancer models to chemotherapy. Eur J Cardiothorac Surg 40(1):e29–e33PubMedCrossRef

Lanier LL, Testi R, Bindl J et al (1989) Identity of Leu-19 (CD56) leukocyte differentiation antigen and neural celladhesion molecule. J Exp Med 169(6):2233–2238PubMedCrossRef

Robertson MJ, Ritz J (1990) Biology and clinical relevance of human natural killer cells. Blood 76(12):2421–2438PubMed

Woll PJ, O’Brien M, Fossella F, Shah M, Clinch Y (2010) Phase I study of lorvotuzumab mertansine (IMGN901) in patients with CD56-positive solid tumors. Ann Oncol Off J Eur Soc Med Oncol 21(Suppl. 8):viii175

10.

Jusufovic E, Iljazovic E, Kosnik M et al (2011) Local CD4+, CD8+ and CD56+ reactions to lung cancer in regard topathohistological type and clinical stage. Med Glas Ljek komore Zenicko-doboj kantona 8(1):101–108PubMed

11.

Al OSY, Marshall E, Middleton D, et al (2012) Increased numbers but functional defects of CD56+ CD3+ cells in lung cancer. Int Immunol 24(7):409–415

12.

Egashira M, Kawamata N, Sugimoto K et al (1999) P-glycoprotein expression on normal and abnormally expanded natural killer cells and inhibition of P-glycoprotein function by cyclosporin A and its analogue, PSC833. Blood 93(2):599–606PubMed

13.

Abraham J, Edgerly M, Wilson R et al (2009) A phase I study of the P-glycoprotein antagonist tariquidar in combination with vinorelbine. Clin Cancer Res 15(10):3574–3582PubMedCrossRef

14.

Morschhauser F, Zinzani PL, Burgess M et al (2007) Phase I/II trial of a P-glycoprotein inhibitor, Zosuquidar.3HCl trihydrochloride (LY335979), given orally in combination with the CHOP regimen in patients with non-Hodgkin’s lymphoma. Leuk Lymphoma 48(4):708–715PubMedCrossRef

15.

Strati A, Markou A, Parisi C et al (2011) Gene expression profile of circulating tumor cells in breast cancer by RT-qPCR. BMC Cancer 11:422PubMedCrossRef

16.

Zhou J, Liu M, Aneja R et al (2006) Reversal of P-glycoprotein-mediated multidrug resistance in cancer cells by the c-Jun NH2-terminal kinase. Cancer Res 66(1):445–452PubMedCrossRef

17.

Hu X, Wu N, Xia P et al (2012) Correlation between low-level expression of the tumor suppressor gene TAp73 and the chemoresistance of human glioma stem cells. Cancer Chemother Pharmacol 69(5):1205–1212PubMedCrossRef

18.

Schmittgen TD, Livak KJ (2008) Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc 3(6):1101–1108PubMedCrossRef

19.

Stewart A, Steiner J, Mellows G et al (2000) Phase I trial of XR9576 in healthy volunteers demonstrates modulation of P-glycoprotein in CD56+ lymphocytes after oral and intravenous administration. Clin Cancer Res 6(11):4186–4191PubMed

20.

d’Amato TA, Landreneau RJ, McKenna RJ et al (2006) Prevalence of in vitro extreme chemotherapy resistance in resected nonsmall-cell lung cancer. Ann Thorac Surg 81(2):440–446 (discussion 446–447)PubMedCrossRef

21.

Carr LL, Finigan JH, Kern JA (2011) Evaluation and treatment of patients with non-small cell lung cancer. Med Clin North Am 95(6):1041–1054PubMedCrossRef

22.

Schena M, Guarrera S, Buffoni L et al (2012) DNA repair gene expression level in peripheral blood and tumour tissue from non-small cell lung cancer and head and neck squamous cell cancer patients. DNA Repair (Amst) 11(4):374–380CrossRef

23.

Wang LE, Yin M, Dong Q et al (2011) DNA repair capacity in peripheral lymphocytes predicts survival of patients with non-small-cell lung cancer treated with first-line platinum-based chemotherapy. J Clin Oncol 29(31):4121–4128PubMedCrossRef

24.

Kelly RJ, Draper D, Chen CC et al (2011) A pharmacodynamic study of docetaxel in combination with the P-glycoprotein antagonist tariquidar (XR9576) in patients with lung, ovarian, and cervical cancer. Clin Cancer Res 17(3):569–580PubMedCrossRef

25.

Bates SE, Bakke S, Kang M et al (2004) A phase I/II study of infusional vinblastine with the P-glycoprotein antagonist valspodar (PSC 833) in renal cell carcinoma. Clin Cancer Res 10(14):4724–4733PubMedCrossRef

26.

Moon YJ, Zhang S, Morris ME (2007) Real-time quantitative polymerase chain reaction for BCRP, MDR1, and MRP1 mRNA levels in lymphocytes and monocytes. Acta Haematol 118(3):169–175PubMedCrossRef

27.

Robey R, Bakke S, Stein W et al (1999) Efflux of rhodamine from CD56+ cells as a surrogate marker for reversal of P-glycoprotein-mediated drug efflux by PSC 833. Blood 93(1):306–314PubMed

28.

Filipits M, Haddad V, Schmid K et al (2007) Multidrug resistance proteins do not predict benefit of adjuvant chemotherapy in patients with completely resected non-small cell lung cancer: international Adjuvant Lung Cancer Trial Biologic Program. Clin Cancer Res 13(13):3892–3898PubMedCrossRef

29.

Liang G, Tang A, Lin X et al (2010) Green tea catechins augment the antitumor activity of doxorubicin in an in vivo mouse model for chemoresistant liver cancer. Int J Oncol 37(1):111–123PubMed

30.

Gyemant N, Engi H, Schelz Z et al (2010) In vitro and in vivo multidrug resistance reversal activity by a Betti-base derivative of tylosin. Br J Cancer 103(2):178–185PubMedCrossRef

31.

Daoud R, Kast C, Gros P et al (2000) Rhodamine 123 binds to multiple sites in the multidrug resistance protein (MRP1). Biochemistry 39(50):15344–15352PubMedCrossRef

32.

Leite DF, Echevarria-Lima J, Salgado LT et al (2006) In vivo and in vitro modulation of MDR molecules in murine thymocytes. Int Immunopharmacol 6(2):204–215PubMedCrossRef

33.

Meaden ER, Hoggard PG, Khoo SH et al (2002) Determination of P-gp and MRP1 expression and function in peripheral blood mononuclear cells in vivo. J Immunol Methods 262(1–2):159–165PubMedCrossRef

34.

Nemoto K, Yoshida K, Nisimura M et al (1991) The effects of Cepharanthin on the recovery of hematopoietic stem cells after X-ray irradiation. Gan To Kagaku Ryoho 18(1):81–84PubMed

35.

Furusawa S, Wu J (2007) The effects of biscoclaurine alkaloid cepharanthine on mammalian cells: implications for cancer, shock, and inflammatory diseases. Life Sci 80(12):1073–1079PubMedCrossRef

36.

Igari R, Iseki K, Abe S et al (2010) Binocular diplopia and ptosis due to snakebite (Agkistrodon blomhoffi “mamushi”)—a case report. Brain Nerve 62(3):273–277PubMed

37.

Enokida H, Gotanda T, Oku S et al (2002) Reversal of P-glycoprotein-mediated paclitaxel resistance by new synthetic isoprenoids in human bladder cancer cell line. Jpn J Cancer Res 93(9):1037–1046PubMedCrossRef

38.

Song YC, Xia W, Jiang JH et al (2005) Reversal of multidrug resistance in drug-resistant cell line EAC/ADR by cepharanthine hydrochloride and its mechanism. Yao Xue Xue Bao 40(3):204–207PubMed

39.

Li H, Yan Z, Ning W et al (2011) Using rhodamine 123 accumulation in CD8 cells as a surrogate indicator to study the P-glycoprotein modulating effect of cepharanthine hydrochloride in vivo. J Biomed Biotechnol 2011:281651PubMed

Title: Increased expression and function of P-glycoprotein in peripheral blood CD56+ cells is associated with the chemoresistance of non-small-cell lung cancer
Authors: Li Han
Ya Feng Wang
Yan Zhang
Ning Wang
Xiao Juan Guo
Jing Ke Yang
Kui Peng Wang
Su Na Liu
Qing Xia Fan
Ke Li
Jin Hua Jiang
Qing Duan Wang
Publication date: 01-09-2012
Publisher: Springer-Verlag
Published in: Cancer Chemotherapy and Pharmacology / Issue 3/2012
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI: https://doi.org/10.1007/s00280-012-1915-x

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 3/2012

Phase I study of the Aurora B kinase inhibitor barasertib (AZD1152) to assess the pharmacokinetics, metabolism and excretion in patients with acute myeloid leukemia

Barbigerone, an isoflavone, inhibits tumor angiogenesis and human non-small-cell lung cancer xenografts growth through VEGFR2 signaling pathways

Anti-proliferative effect of 23,24-dihydrocucurbitacin F on human prostate cancer cells through induction of actin aggregation and cofilin-actin rod formation

Antiangiogenic therapy in the management of brain tumors: a clinical overview

Phase 1 study of ganitumab (AMG 479), a fully human monoclonal antibody against the insulin-like growth factor receptor type I (IGF1R), in Japanese patients with advanced solid tumors

A phase I trial of oral administration of panobinostat in combination with paclitaxel and carboplatin in patients with solid tumors

Keynote webinar | Spotlight on antibody–drug conjugates in cancer